Immune tolerance induction in patients with haemophilia A with inhibitors: A systematic review

Haemophilia

Volumn 9, Issue 4, 2003, Pages 436-463

  Wight, J ^a   Paisley, S ^a   Knight, C ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Haemophilia A; Immune tolerance induction; Inhibitors; Systematic review

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; AZATHIOPRINE; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; RECOMBINANT BLOOD CLOTTING FACTOR 8; VINCRISTINE;

BLEEDING; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFIDENCE INTERVAL; COST BENEFIT ANALYSIS; DRUG DOSE REGIMEN; DRUG INHIBITION; EXPERIMENTAL DESIGN; HEMOPHILIA A; HUMAN; IMMUNOLOGICAL TOLERANCE; INFORMATION PROCESSING; PRIORITY JOURNAL; REGISTER; RELAPSE; REVIEW; TREATMENT OUTCOME;

EID: 0038383604     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.2003.00781.x     Document Type: Review

References (54)

1. Hedner U, Tengborn L. Management of haemophilia A with antibodies - the effect of combined treatment with factor VIII, hydrocortisone and cyclophosphamide. Thromb Haemost 1985; 54: 776-9.
2. Stein RS, Colman RW. Hemophilia with factor VIII inhibitor. Elimination of anamnestic response. Ann Int Med 1973; 79: 84-7.
3. Dormandy KM, Sultan Y. The suppression of factor VIII antibodies in haemophilia. Pathol Biol (Paris) 1975; 23 (Suppl.): 17-23.
4. Hultin MB, Shapiro SS, Bowman HS et al. Immunosuppressive therapy of factor VIII inhibitors. Blood 1976; 48: 95-108.
5. Hruby MA, Schulman I. Failure of combined factor VIII and cyclophosphamide to suppress antibody to factor VIII in hemophilia. Blood 1973; 42: 919-23.
6. Lian ECY, Larcada AF, Chiu AY. Combination immunosuppressive therapy after factor VIII infusion for acquired factor VIII inhibitor. Ann Int Med 1989; 110: 774-8.
7. Dormandy KM. Immunosuppression in the Treatment of Haemophiliacs with antibodies to Factor VIII. In: Proceedings of the IXth Congress, World Federation of Haemophilia, Istanbul. Excerpta Medica 1975: 225-39.
8. Brackman HH, Gormsen J. Massive factor VIII infusion in haemophiliac with factor VIII inhibitor, high responder. Lancet 1977; 2: 933.
9. Rizza CR, Matthews JM. Effect of frequent factor VIII replacement on the level of factor VIII antibodies in haemophiliacs. Br J Haematol 1982; 52: 13-24.
10. Centre for Evidence Based Medicine. Levels of evidence and grades of recommendation. http://www.cebm.j-r2.ox.ac.uk. 2001.
11. Sultan Y. Immune tolerance protocols using low-dose factor VIII: a review of the literature. Vox Sang 1999; 77 (Suppl. 1): 55-6.
12. Van Leeuwen EF, Mauser-Bunschoten EP, Van Dijken PJ et al. Disappearance of factor VIII:C antibodies in patients with haemophilia A upon frequent administration of factor VIII in intermediate or low dose. Br J Haematol 1986; 64: 291-7.
13. Scheibel E, Ingerslev J, Dalsgaard-Nielsen J, Stenbjerg S, Knudsen JB. Continuous high-dose factor VIII for the induction of immune tolerance in haemophilia A patients with high responder state: a description of eleven patients treated. Thromb Haemost 1987; 58: 1049-52.
14. Rocino A, de Biasi R. Successful immune tolerance treatment with monoclonal or recombinant factor VIII concentrates in high responding inhibitor patients. Vox Sang 1999; 77 (Suppl. 1): 65-9.
15. Rocino A, Papa ML, Salerno E, Capasso F, Miraglia E, de Biasi R. Immune tolerance induction in haemophilia a patients with high-responding inhibitors to factor VIII: Experience at a single institution. Haemophilia 2001; 7: 1-38.
16. Nilsson IM, Berntorp E, Zettervall O. Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII. N Engl J Med 1988; 318: 947-50.
17. Ehrenforth S, Kreuz W, Funk M, Auerswald G, Scharrer I. Variables that might affect the outcome of immune tolerance therapy in haemophiliacs with factor VIII inhibitors. Thromb Haemost 1994; 72: 784-5.
18. Brackmann HH, Oldenburg J, Schwaab R. Immune tolerance for the treatment of factor VIII inhibitors - twenty years' 'Bonn protocol'. Vox Sang 1996; 70 (Suppl. 1): 30-5.
19. Kreuz W, Ehrenforth S, Funk M et al. Immune tolerance therapy in pediatric haemophiliacs with factor VIII inhibitors: 14 years follow up. Haemophilia 1995; 1: 24-32.
20. Oldenburg J, Schwaab R, Brackmann HH. Induction of immune tolerance in haemophilia A inhibitor patients by the 'Bonn Protocol': predictive parameter for therapy duration and outcome. Vox Sang 1999; 77 (Suppl. 1): 49-54.
21. Lilleyman JS. Domiciliary desensitization therapy for young boys with haemophilia and factor VIII inhibitors. Br J Haematol 1994; 86: 433-5.
22. Unuvar A, Warrier I, Lusher JM. Immune tolerance induction in the treatment of pediatric haemophilia A patients with factor VIII inhibitors. Haemophilia 2000; 6: 150-7.
23. Smith MP, Spence KJ, Waters EL et al. Immune tolerance therapy for haemophilia A patients with acquired factor VIII alloantibodies: comprehensive analysis of experience at a single institution. Thromb Haemost 1999; 81: 35-8.
24. Mariani G, Ghirardini A, Bellocco R. Immune tolerance in hemophilia-principal results from the International Registry. Report of the factor VIII and IX Subcommittee. Thromb Haemost 1994; 72: 155-8.
25. Ghirardini A, Puopolo M, Chiarotti F, Mariani G. The international registry of immune tolerance: 1994 update. Vox Sang 1996; 70 (Suppl. 1): 42-6.
26. Mariani G, Kroner B. International immune tolerance registry, 1997 update. Vox Sang 1999; 77 (Suppl. 1): 25-7.
27. DiMichele DM, Kroner BL. Analysis of the North American Immune Tolerance Registry (NAITR) 1993-1997: current practice implications. ISTH Factor VIII/IX Subcommittee Members. Vox Sang 1999; 77 (Suppl. 1): 31-2.
28. Lenk H. The German National Immune Tolerance Registry, 1997 update. Study Group of German Haemophilia Centres. Vox Sang 1999; 77 (Suppl. 1): 28-30.
29. Lenk H, Brackmann HH, Auerswald G et al. The German registry of immune tolerance treatment in hemophilia - 1999 Update. Haematologica 2000; 85 (Suppl. 10): 45-7.
30. Haya S, Lopez MF, Aznar JA, Battle J. Immune tolerance treatment in haemophilia patients with inhibitors: the Spanish Registry. Haemophilia 2001; 7: 154-9.
31. Damiano ML, Hutter JJ. Immune tolerance for haemophilia patients with inhibitors: analysis of the western United States experience. The Tri-Regional Nursing Group. Haemophilia 2000; 6: 526-32.
32. Brackmann HH. Induced immunotolerance in factor VIII inhibitor patients. Prog Clin Biol Res 1984; 150: 181-95.
33. Berntorp E, Nilsson IM. Immune tolerance and the immune modulation protocol. Vox Sang 1996; 70 (Suppl. 1): 36-41.
34. Berntorp E, Astermark J, Carlborg E. Malmo protocol update. Haematologica 2000; 85 (Suppl. 10): 48-51.
35. Mauser-Bunschoten EP, Nieuwenhuis HK, Roosendaal G, van den Berg HM. Low-dose immune tolerance induction in hemophilia A patients with inhibitors. Blood 1995; 86: 983-8.
36. Mauser-Bunschoten EP, Roosendaal G, van den Berg HM. Low-dose immune tolerance therapy: the van Creveld model. Vox Sang 1996; 70 (Suppl. 1): 66-7.
37. Ewing NP, Sanders NL, Dietrich SL, Kasper CK. Induction of immune tolerance to factor VIII in hemophiliacs with inhibitors. JAMA 1988; 259: 65-8.
38. Ewing NP. Induction of immune tolerance with factor VIII concentrate in patients with hemophilia A and inhibitors. Prog Clin Biol Res 1990; 324: 59-68.
39. Kucharski W, Scharf R, Nowak T. Immune tolerance induction in haemophiliacs with inhibitor to FVIII: high- or low-dose programme. Haemophilia 1996; 2: 224-8.
40. Aznar JA, Jorquera JI, Peiro A, Garcia I. The importance of corticoids added to continued treatment with factor VIII concentrates in the suppression of inhibitors in haemophilia A. Thromb Haemost 1984; 51: 217-21.
41. Hay CR, Laurian Y. Induction of tolerance using porcine factor VIII. Vox Sang 1996; 70 (Suppl. 1): 68-9.
42. Freiburghaus C, Berntorp E, Ekman M, Gunnarsson M, Kjellberg B, Nilsson IM. Tolerance induction using the Malmo treatment model 1982-1995. Haemophilia 1999; 5: 32-9.
43. Carlborg E, Astermark J, Lethagen S, Ljung R, Berntorp E. The Malmo model for immune tolerance induction: impact of previous treatment on outcome. Haemophilia 2000; 6: 639-42.
44. Mauser-Bunschoten EP, Roosendaal G, Bruin M, Van Dijken PJ. Disappearance of factor VIII antibodies upon frequent administration of factor VIII. Folia Haematol 1990; 117: 533-7.
45. Gruppo RA, Valdez LP, Stout RD. Induction of immune tolerance in patients with hemophilia A and inhibitors. Am J Pediatr Hematol Oncol 1992; 14: 82-7.
46. Mariani G, Solinas S, Pasqualetti D et al. Induction of immunotolerance in hemophilia for high titre inhibitor eradication: a long-term follow-up. Thromb Haemost 1989; 62: 835-9.
47. Stenbjerg S, Jorgensen J, Tauris P, Skottun T. Low dose factor VIII for the treatment of hemophilia with inhibitors. In: Mariani G, Russo MA, Mandelli F, eds. Activated Prothrombin Complex Concentrates. New York: Praeger, 1982: 206-13.
48. Batlle J, Lopez MF, Brackmann HH et al. Induction of immune tolerance with recombinant factor VIII in haemophilia A patients with inhibitors. Haemophilia 1999; 5: 431-5.
49. Hay CR, Laurian Y, Verroust F, Preston FE, Kernoff PB. Induction of immune tolerance in patients with hemophilia A and inhibitors treated with porcine VIIIC by home therapy. Blood 1990; 76: 882-6.
50. Mariani G, Kroner B, ITSG. Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success. Haematologia 2001; 86: 1186-93.
51. Hind D, Lloyd Jones M. Management of inhibitors in people with haemophilia A (Cochrane Review). The Cochrane Library Oxford: Update Software, 2003 (to be published in 2003).
52. Gruppo RA. The use of porcine factor VIII during immune tolerance induction therapy with human factor VIII. Blood Coagul Fibrinolysis 1991; 2: 37-42.
53. Hay CR. Innovative use of porcine factor VIII:C for immune tolerance induction. Am J Med 1991; 91: 27S-9S.
54. Mariani G, Scheibel E, Nogao T et al. Immunetolerance as treatment of alloantibodies to factor VIII in hemophilia. The International Registry of Immunetolerance Protocols. Semin Hematol 1994; 31 (2 Suppl. 4): 62-4.